In their comments on our recent paper, Standing et al. [1] raise questions about the plausibility of the (de)maturationfunction used to describe differences in the clearance of lamotrigine, where patients younger than 2 years of age show, on average, a higher clearance than adults after correction for body weight. The authors discuss three possible scenarios that could lead to model misspecification. Whilst their arguments highlight important points to consider during model development and evaluation, we contest these points on a case-by-case basis and provide additional evidence for the increase in clearance and proposed (de)maturation function.
The inclusion of elderly subjects does not lead to bias
Although we acknowledge that the step function used to describe changes in the apparent total clearance of the drug from plasma after oral administration (CL/F) in patients > 65 years of age is arbitrary (i.e. the cut-off age was not estimated), the available pharmacokinetic data suggest a clear change relative to the values observed in the younger adult population. It is not uncommon to model this decline as a step function that centres around 65 years of age [2] [3] [4] , even though a continuous inflection point model has been used before to describe the same phenomenon [5] . Unfortunately, the development of a more elaborate model was not possible with the available data. Nevertheless, the proposed parameterisation should not affect CL/F estimates in adults or children, as a larger portion of our data concerns adults aged < 65 years (n = 208, partially dense sampled data), compared with elderly individuals (n = 116, only sparse data). If the use of a step function represented a potential misspecification, we would have expected convergence or boundary issues during the minimisation steps or estimates with high imprecision from the covariance step or bootstrap analysis. In fact, the inclusion of the step function was evaluated before extending our modelling exercise to children, and resulted in a statistically significant drop in the objective function, with reasonable precision in the parameter estimates. The CL/F estimates for the adult population based on adult data only were similar to the final model using all data ( 
No impact of imbalance in co-medication use
Admittedly, the distribution of co-medications is different in subpopulation F (n = 144, age 1-24 months) when compared with the adult population (see Table 1S , supplementary material in van Dijkman et al. [7] ). Few patients received co-medications known to have an effect on the clearance of lamotrigine, i.e. carbamazepine (n = 3), phenytoin (n = 3) or valproic acid (n = 3). Most notably, 24 patients received phenobarbital, which was shown to increase lamotrigine clearance in previous investigations [4, 8, 9] . Despite these findings, the effect of phenobarbital on CL/F was not statistically significant. Clearance estimates varied by approximately 17%, but this effect resulted in a decrease in the objective function of only 1.46 (p > 0.05). In addition, clearance estimates were not significantly affected by phenobarbital even if the maturation function is omitted (3.4 vs. 3.29 L/h, respectively, without and with the effect of phenobarbital as a covariate). 4. Further evidence of higher apparent clearance in young children Our study is not the first to show that lamotrigine clearance may be higher in infants and toddlers, as compared with older children or adults [10, 11] . Mikati et al. found that "apparent clearance increased during the first year of life, with a break point at 2 months of age" [12] . Their estimate for clearance in infants and toddlers was 0.217 L/h. Similarly, He et al. have evaluated the pharmacokinetics of lamotrigine in Chinese children and reported even higher values for clearance (i.e. 0.53 L/h for a 1-year-old, 10-kg child) [8] . Other publications describe lower peak plasma concentrations and systemic exposure (area under the plasma concentrationtime curve) in young children [13] . Furthermore, basic research on drug metabolism shows evidence of temporal specific enzyme expression patterns or developmental trajectories, which result in age-dependent changes in the activity of metabolising enzymes [14, 15] . For instance, Miyagi et al. have reported a decrease in β-glucuronidase activity with age, whereas UGT activity has been shown to increase with age [16] . Lastly, we also recognise the potential for confounding as a result of other covariate factors, such as genetic polymorphisms. It is commonly accepted that lamotrigine is primarily glucuronidated by UGT-1A4. However, UGT2B7 and UGT1A3 have also been suggested to play a (minor) role in the biotransformation of lamotrigine [17, 18] . In fact, the polymorphism in UGT2B7 has been associated with variability in the clearance of lamotrigine. Clearance was 117% higher (95% confidence interval 44.8-247) in patients with the UGT2B7 372 GG genotype, as compared with the AA genotype [18] . Unfortunately, genotype data were not available for our analysis.
Given the contribution of different enzyme expression patterns and developmental trajectories to the elimination of lamotrigine, we deem as unlikely that the (de)maturation function results from the imbalance in the number of children between 4 and 12 years of age. This is further highlighted in Fig. 1 , in which individual clearance values estimated by a model without a (de)maturation function and without covariates for the elderly population are presented. It can be seen that clearance in the first 2 years of life is considerably higher, when adjusted for weight using allometry. Although at present we cannot determine the mechanisms underlying the observed developmental trajectory, it cannot be excluded that while UGT-1A4 activity is lower at a younger age, higher activity of the other isozymes (UGT2B7 and UGT1A3) may contribute to the observed increase in clearance. Further studies including genotyping are required to corroborate these findings.
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